Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
240
-
Total 13F shares, excl. options
-
82.5M
-
Shares change
-
-1.62M
-
Total reported value, excl. options
-
$7.5B
-
Value change
-
-$82.7M
-
Put/Call ratio
-
1.3
-
Number of buys
-
125
-
Number of sells
-
-118
-
Price
-
$90.93
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q4 2020
281 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q4 2020.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 240 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.5M shares
of 114M outstanding shares and own 72.12% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (12.6M shares), FMR LLC (7.6M shares), VANGUARD GROUP INC (6.78M shares), BlackRock Inc. (6.67M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.51M shares), Casdin Capital, LLC (3.05M shares), FARALLON CAPITAL MANAGEMENT LLC (3M shares), ARK Investment Management LLC (2.9M shares), JANUS HENDERSON GROUP PLC (2.55M shares), and Bellevue Group AG (2.11M shares).
This table shows the top 240 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.